April 2019, Volume 69, Issue 8

Animal Research

Rosuvastatin Attenuates acute nephrotoxicity through modulation of oxidative stress in Sprague Dawley rats

Authors: Huda Abdulbaki Rasheed  ( Department of Clinical Pharmacology, Medicine and Therapeutic, Al- Mustansiriya University, Baghdad, Iraq )
Hayder M. Al-kuraishy  ( Department of Clinical Pharmacology, Medicine and Therapeutic, Al- Mustansiriya University, Baghdad, Iraq )
Ali I. Al-Gareeb  ( Department of Clinical Pharmacology, Medicine and Therapeutic, Al- Mustansiriya University, Baghdad, Iraq )


Objectives: To assess the reno-protective effect of rosuvastatin on gentamicin-induced nephrotoxicity in rats.
Methods: The prospective experimental study was conducted at the College of Medicine, Mustansiriya University, Baghdad, Iraq, from March to July, 2018, and comprised Sprague Dawley male rats aged 3-4 months and weighing 200-400g each. The rats were divided into 3 equal groups which were treated for 14 days. Group1 was treated with distilled water plus normal saline, Group2 with distilled water plus gentamicin, and Group3 with rosuvastatin plus gentamicin. Parameters measured were blood urea, serum creatinine, serum malondialdehyde, superoxide dismutase, glutathione reductase, neutrophil gelatinase associated lipocalin, kidney injury molecule-1, interleukin- 18 and Cystatin-c. SPSS 20 was used for data analysis.
Results: Of the 30 rats, there were 10(33.3%) in each of the three groups. Rosuvastatin produced significant renoprotective effect through reduction of blood urea, kidney injury molecule-1 and interleukin-18 (p<0.01) compared to the gentamicin group.
Conclusion: Rosuvastatin was found to be a reno-protective against
gentamicin-induced nephrotoxicity through modulation of pro-inflammatory and oxidative/anti-oxidant pathways.
Keywords: Gentamicin, Rosuvastatin, Nephroprotective effect, Nephrotoxicity. (JPMA 69: S-98 (Suppl. 3); 2019)


Gentamicin is a bactericidal antibiotic used for treatment of different bacterial infections. It is mostly used for the treatment of urinary tract infection (UTI), pneumonia, bone infection, meningitis and pelvic inflammatory diseases.1,2 Gentamicin gets selectively deposited in the epithelial cells of proximal renal tubules, leading to acute nephrotoxicity.3 The selective accumulation of gentamicin at renal tubules is due to the presence of megalin and cubilin which are membrane endocytic proteins at proximal renal tubules that are involved in the transport of cations such as aminoglycosides and xenobiotics. This accumulation alters the function of epithelial cells of proximal renal tubules via the alteration of extra-cellular calcium sensing receptors, leading to necrosis and cell death. 4 Chronic or high dose of gentamicin initiates free radical generations and induction of oxidative stress. Furthermore, gentamicin at proximal renal tubules activates mitochondrial superoxide anions causing generation of free radicals. Besides, gentamicin stimulates the mitochondrial respiratory chain that generates free radicals. 5 Previous studies documented that gentamicin therapy leads to significant reduction in the activity of glutathione, superoxide dismutase (SOD) and other endogenous antioxidants' at renal proximal tubular cells that contribute in part in gentamicin-induced nephrotoxicity. Therefore, anti-oxidant agents carry reno-protective effects and reduce nephrotoxcity via the reduction of tissue damage and oxidative stress. 6 Therapy with reduced glutathione fails in the prevention of gentamicin-induced nephrotoxicity despite the reduction of lipid peroxidation and increment in the renal glutathione activity as gentamicin produces dose-dependent effects. 7 Rosuvastatin is a synthetic lipid-lowering agent which is a competitive inhibitor of hydroxymethylglutarylcoenzyme A(HMG-CoA) reductase enzyme. Rosuvastatin is a rate-limiting enzyme in the conversion of HMG-CoA to mevalonate, reduces the level of low-density lipoprotein (LDL) and triglycerides (TG), and it increases the level of high-density lipoprotein (HDL). Also, rosuvastatin has significant reno-protective effect due to its anti-oxidant and free radical scavenging effects. 8,9 The current study was planned to evaluate the renoprotective effect of rosuvastatin in gentamicin-induced nephrotoxicity in rats.

Materials and Methods

The prospective experimental placebo-controlled study was conducted at the Department of Pharmacology, College of Medicine, Mustansiriya University, Baghdad, Iraq, from March to July, 2018, and comprised Sprague Dawley male rats aged 3-4 months and weighing 200-400g each. The animals were obtained from the Iraqi National Centre of Cancer and Genetic Researches, University of Baghdad. The animals were isolated as 3 rats in each cage and placed at suitable room temperature under artificial 12/12hr light-dark cycle. They were left for one week for acclimatisation without any intervention and with free access to normal chow pellets and water ad libitum. Permission for the study was obtained from the institutional ethics committee in accordance with the Guide to the Care and Use of Laboratory Animal. 10The study protocol for the induction of nephrotoxicity was in line with literature. 11 Group 1 rats were treated with distilled water 5 ml/kg orally for 14 days, and on days 6-14 they received an intra-peritoneal injection of normal saline 5 ml/kg daily. Group 2 rats treated with distilled water 5 ml/kg orally for 14 days, and on days 6-14 they received intraperitoneal injection of gentamicin 100 mg/kg. Group 3 rats were treated with rosuvastatin 10 mg/kg orally for 14 days, and on days 6-14 they received an intraperitoneal injection of gentamicin 100 mg/kg at an interval of 1h.

Estimated glomerular filtration rate (eGFR) was measured

according to Schwartz formula, eGFR =k × height

(cm)/serum creatinine (mg/dl), K=0.55. 12

The next step was the assessment of anthropometric variables. Length was measured by graduated tape from nose to the anus (naso-anal length in cm). Bodyweight was measured by specific digital balance in gram. Body mass index (BMI) was calculated as body weight in grams divided by the square of length in cm; BMI=BW (grams)/length (cm)2.13 On day 15, rat decapitation was done under chloroform anaesthesia. The blood sample was centrifuged for 10 minutes at 5000rpm at room temperature. The isolated samples were kept at -20°C till assessment. Among biochemical variables, blood urea and serum creatinine were estimated by using an auto-analyzer (ILab-300-Biomerieux Diagnostic, Milano, Italy) and they were expressed as mg/dL. Serum malondialdehyde (MDA), SOD, glutathione reductase (GSH), neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18) and Cystatin-c (Cyst-c) were measured using enzyme-linked immunosorbent assay (ELISA) according to the instructions given on the kit the the manufacturer (Myobio source, USA). Data analysis was done using SPSS 20, and it was presented as mean} standard deviation (SD). The variables were tested using unpaired student t-test to compare the control and the treated groups. The levels of significance was set at p<0.05.


Of the 37 rats assessed, 30(81%) comprised the final sample, with 10(33.3%) in each of the three groups(Figure-1).

Throughout gentamicin-induced nephrotoxicity, blood urea and serum creatinine increased significantly while eGFR decreased significantly in the gentamicin group compared to the control group (p<0.05). There were non-significant increase in the MDA serum levels and non-significant decrease in SOD and GSH levels in the gentamicin group compared to the control group (p>0.05). Also, there was significant increase in IL-18, KIM-1 and NGAL levels compared to the control group (Table-1).

Blood urea increased from 56.87}9.33mg/dL in the gentamicin group compared to 40.25}8.95mg/dL in the rosuvastatin group (p=0.002), while serum creatinine got reduced non-significantly (p>0.05). IL-18 and KIM-1 were reduced in the rosuvastatin group compared to the gentamicin group, as they were 242.63}21.78pg/mL compared to 494.36}69.32pg/mL, and 154.58}33.59pg/mL compared to 354.98}46.38 pg/ml. Rosuvastatin showed non-significant reduction of Cyst-c serum levels in gentamicin induced nephrotoxicity (Figure-2).


The present study definitely demonstrated that gentamicin was brilliant to induced experimental nephrotoxicity in rats via significant elevation of blood urea and serum creatinine. These findings corresponded with a recent study. 13 It has been established that generation of free radicals and induction of oxidative stress are the main pathways of gentamicin-induced nephron toxicity. Overproduction of reactive oxygen species is linked with depletion of proximal renaltubules' anti-oxidant potential which is subsequently developed into lipid peroxidation and tubular damages. 15 Therefore, serum level of MDA is elevated while SOD and GSH levels are reduced in different models of gentamicin-induced-nephrotoxicity. 16 Despite these findings, gentamicin in the present study increased MDA serum levels, reduced SOD and GSH nonsignificantly which might be due to insufficient gentamicin dose, small sample  size or short duration of the study.The present study also showed significant elevation in IL-18 serum levels in gentamicin-induced nephrotoxicity which corresponds with a recent study that pointed to the benefit of IL-18 serum levels in the prediction of nephrotoxicity and acute kidney injury (AKI). IL-18 serum level is elevated prior to the elevation of blood urea and serum creatinine as it is highly sensitive and specific. 17 The present study also illustrated significant effect of gentamicin in the elevation of KIM-1 and NGAL as both sera level are sensitive and specific biomarkers and are correlated with gentamicin-induced nephrotoxicity within seven days. However, the increment in those biomarkers is time- and dosedependent due to the progressive gene expression of KIM-1 and NGAL. 18Moreover, the present study illustrated significant elevation in Cyst-c serum level in gentamicin-induced nephrotoxicity compared to the controls due to glomerular damage. Peng et al. study confirmed that elevation of serum Cyst-c indicated glomerular damage while elevation of urinary Cyst-c indicated renal tubular damage. 19 The present study recognised that rosuvastatin had renoprotective effect through reduction of blood urea significantly, as supported by a study that confirmed the reno-protective effect of rosuvastatin against amikacininduced nephrotoxicity. 20 Nevertheless, rosuvastatin produced insignificant amelioration of serum creatinine and eGFR which might be due to the short duration of the study. Rosuvastatin has potent anti-oxidant, free radical scavenging and anti-inflammatory effects. The anti-inflammatory effect of rosuvastatin was well revealed through significant reduction of IL-18 compared to the gentamicin group which was in line with a study that discussed the immunological effect of rosuvastatin and inhibition of IL-18 by rosuvastatin pharmacotherapy. 21 In spite of these facts, rosuvastatin in the present study was unsuccessful in producing the anti-oxidant effect and reduction of MDA which is the biomarker of lipid peroxidation and oxidative stress. The non-significant effect might be due to small dose and/or short duration of the study. A study illustrated non-significant effect of rosuvastatin and atorvastatin on the oxidative stress in thioacetamide-induced liver cirrhosis. 22 The reno-protective effects of rosuvastatin are linked to different pleiotropic effects that affect renal vasculature via augmentation of endothelium-dependent mechanism, anti-platelet effects, inhibition of vasoconstrictor endothelin-1 and reduction of renal inflammation. 23 Similarly, a study accounted that rosuvastatin played a role in the prevention of renal injury through the attenuation of tubule-interstitial fat deposition via inhibition of matrix metallopeptidase 9 (MMP-9) and MMP-2 which participate in the renal inflammation and AKI. 24 Gentamicin and other aminoglycosides are selectively accumulated at proximal convoluted tubules via megalin receptors. 3 Rosuvastatin inhibits megalin-dependent endocytosis so it attenuates gentamicininducednephrotoxicity. 12Furthermore, a study established that hydrophilic statins, including rosuvastatin and pravastatin, are more effective in the reduction of lipid accumulations at renal tubules than lipophilic statins, including atorvastatin and pitavastatin. 26 Despite borderline results, rosuvastatin has nephro-protective given that tubular effect regarding KIM-1 was more than glomerular effect regarding NGAL.


Rosuvastatin led to significant reno-protective effect against gentamicin-induced nephrotoxicity through modulation of pro-inflammatory and oxidative/antioxidant pathways.

Acknowledgment: We are grateful to Prof. Dr. Sadiq M. Al-Hamash for his great support.
Disclaimer: None.
Conflicts of Interest: None.
Source of Support: None.


1. A V, S A, Kuriakose J, Midhun SJ, Jyothis M, Latha MS. Protective effect of Rotula aquaticaLour against gentamicin induced oxidative stress and nephrotoxicity in Wistar rats. Biomed  Pharmacother2018;106:1188-94.
2. Van Nieuwkoop C, Den Exter PL, Elzevier HW, Den Hartigh J, Van Dissel JT. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents 2010;36:485-90.

3. Al-Kuraishy HM, Al-Gareeb AI, Al-Naimi MS. Pomegranate attenuates acute gentamicin-induced nephrotoxicity in spraguedawley rats: the potential antioxidant and anti-inflammatory effects. Asian J Pharm Clin Res 2019;12:484-6
4. Al-Kuraishy HM, Al-Gareeb AI, Rasheed HA. Antioxidant and anti-inflammatory effects of curcumin contribute into attenuation of acute gentamicin-induced nephrotoxicity in rats. Asian J Pharm Clin Res 2019;12:466-8.
5. Hajihashemi S, Jafarian T, Ahmadi M, Rahbari A, Ghanbari F. Ameliorative effects of zataria multiflora hydro-alcoholic extract on gentamicin induced nephrotoxicity in rats. Drug Res (Stuttg) 2018;68:387-94.
6. Al-Kuraishy HM, Al-Gareeb AI, Hussien NR. Betterment of diclofenac-induced nephrotoxicity by pentoxifylline through modulation of inflammatory biomarkers. Asian J Pharm Clin Res 2019;12:433-7.

7. Shahani S, Behzadfar F, Jahani D, Ghasemi M, Shaki F. Antioxidant and anti-inflammatory effects of Nasturtium officinale involved in attenuation of gentamicin-induced nephrotoxicity. Toxicol Mech Methods 2017;27:107-114.

8. Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadily AK. Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study. J Lab Physicians 2018;10:271-75.

9. Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases 2018;6:e9.

10. National Research Council. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC: The National Academies Press, 2011.
11. Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, et al. Animal models of acute renal failure. Pharmacol Rep 2012;64:31-44.
12. Gacka E, ?yczkowski M, Bogacki R, Paradysz A, Hyla-Klekot L. The Usefulness of Determining Neutrophil Gelatinase-Associated Lipocalin Concentration Excreted in the Urine in the Evaluation of Cyclosporine A Nephrotoxicity in Children with Nephrotic Syndrome. Dis Markers 2016;2016:e6872149.

13. Joda AT, Al-Najar AF, Khalaf MS. Evaluation of Serum Interleukin- 6, Body Mass Index and bone mineral density in Patients with Nodal Osteoarthritis. Mustansiriya Med J2016;15:84-7.

14. Abd-Elhamid TH, Elgamal DA, Ali SS, Ali FEM, Hassanein EHM, El- Shoura EAM, et al. Reno-protective effects of ursodeoxycholic acid against gentamicin-induced nephrotoxicity through modulation of NF-?B, eNOS and caspase-3 expressions. Cell Tissue Res 2018;374:367-87.

15. Alarifi S, Al-Doaiss A, Alkahtani S, Al-Farraj SA, Al-Eissa MS, Al- Dahmash B, et al. Blood chemical changes and renal histological alterations induced by gentamicin in rats. Saudi J Biol Sci 2012;19:103-10.

16. Alkuraishy HM, Al-Gareeb AI, Al-Naimi MS. Pomegranate protects renal proximal tubules during gentamicin inducednephrotoxicity in rats. J Contemp Med Sci 2019;5:35-40.

17. Ren H, Zhou X, Dai D, Liu X, Wang L, Zhou Y, et al. Assessment of urinary kidney injury molecule-1 and interleukin-18 in the early post-burn period to predict acute kidney injury for various degrees of burn injury. BMC Nephrol2015;16:142.
18. Luo QH, Chen ML, Chen ZL, Huang C, Cheng AC, Fang J, et al. Evaluation of KIM-1 and NGAL as early indicators for assessment of gentamycin-induced nephrotoxicity in vivo and in vitro. Kidney

Blood Press Res 2016;41:911-18.
19. Peng ZY, Joyce E, Murugan R, Kellum JA. In: Ronco C, Bellomo R, Kellum JA, Ricci Z, eds. The Role of Biomarkers in the Diagnosis and Management of Acute Kidney Injury: Critical Care Nephrology 3rd ed. Philadelphia: Elsevier, 2019; pp 138-41.

20. Selim A, Khalaf MM, Gad AM, Abd El-Raouf OM. Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin?induced renal injury in rats. J Biochem Mol Toxicol 2017;31:e21957.

21. Weijma RG, Vos ER, Ten Oever J, Van Schilfgaarde M, Dijksman LM,

Van Der Ven A, et al. The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients. Open Forum Infect Dis 2015;3:201.

22. Shirin H, Sharvit E, Aeed H, Gavish D, Bruck R. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. World J Gastroenterol 2013;19:241-8.

23. Al-Kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins. J Lab Physicians 2017;9:163-69.

24. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol2007;170:1165-77.

25. Vlad A, Vlad M, Petrica L, Ursoniu S, Gadalean F, Popescu R, et al.

Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study. Ren Fail 2017;39:112-19.

26. Gotto AM, Moon JE. Statins: Risk-Benefits and Role in Treating Dyslipidemias. Dyslipidemias: Pathophysiology, Evaluation and Management. Totowa NJ: Humana Press, 2015; pp 403-21.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: